KURA Healthcare

Kura Oncology, Inc.

$9.88+0.92%

Price as of close on Nov 3, 2026 · Financials updated Sep 30, 2026

Basics

Sector: Healthcare
Industry: Biotechnology
Country: United States
Market cap: 878.9M USD
Enterprise value: 298.5M USD
Full-time employees: 260

Overall health

Strength: lower risk than most peers: more short-term liquiditylower risk: more liquidity
Drawback: less profitable than most peersless profitable than peers
Drawback: its shares are priced higher than most peers relative to what it earnspriced higher than peers for its earnings
About average: growth

Ranks #889 of 1,157 healthcare companies (bottom 24%)

See how it ranks against its peers

Worth knowing

Shareholders being diluted. Shares outstanding up 30% from December 2022 to August 2026.
Kura Oncology had 30% more shares at August 2026 than at December 2022, mostly from issuing stock (for pay, acquisitions or fundraising). Each existing share now owns a smaller slice of the business.Kura Oncology had 30% more shares at August 2026 than at December 2022, mostly from issuing stock. Each existing share now owns a smaller slice of the business.
Stock-based pay is a large cost. Stock pay was 55% of revenue in 2025.
Kura Oncology paid employees $37M in stock in 2025, 55% of its $67M revenue. It doesn't use cash, so it flatters cash flow, but it is a real cost to shareholders through dilution.
Valuation signals disagree. Cheaper than 50% of peers on free cash flow, but only 0% on earnings.
Relative to its free cash flow, Kura Oncology looks cheaper than 50% of peers; relative to its earnings, cheaper than only 0%. The valuation score blends the two, so look at which measure fits this business best.
Growing fast, still losing money. Revenue grew faster than 83% of peers, at an operating loss.
Revenue grew faster than 83% of peers, but the business runs at an operating loss (margin -412%).

StockQuotient Score

36/ 100

Oct 5 36 → Nov 4 36

Valuation

Is the price right?

8/100

Weak

3/3 inputs reported · High confidence

Since last quarter: No major changeValuation also moves with the share price every day.

Why

Weaker than most peers on:

▼ Earnings yield
▼ EBITDA yield

Compare with peers

Behind the score

Sector-normalized EBITDA, earnings, and free cash flow yields.

Earnings yield-33.8%

SEC filings · 12 months to Jun 2026Negative (a loss or cash outflow), so it counts as zero whatever the share price30% base weight · Z-score -1.00Sector median: 0.0148 · MAD: 0.0148

EBITDA yield-86.9%

SEC filings · 12 months to Jun 2026Negative (a loss or cash outflow), so it counts as zero whatever the share price50% base weight · Z-score -1.00Sector median: 0.0401 · MAD: 0.0401

Free cash flow yield-13.4%

SEC filings · 12 months to Jun 2026 · operating cash flow − capital spendingNegative (a loss or cash outflow), so it counts as zero whatever the share price20% base weight · Z-score 0.00Sector median: 0.0000 · MAD: 0.0000

Other data (not scored)

Book yield5.5%

SEC filings · latest balance sheetReported valueInformational · 0% composite weightSector median: 0.3716 · MAD: 0.2313

Growth

Is it growing?

56/100

Moderate▼ 1 since Oct 27 close

2/3 inputs reported · Partial data

Since last quarter: ▲ Stronger

12-month revenue up 7.8%

Why it changed since the Oct 27, 2026 close: Score 57 → 56

Peer companies moved-1

Each step re-scores the company against its peers as they were on Oct 28, 2026; the parts add up to the change. Price effects on EBITDA yield are approximate.

Why

Mixed versus peers:

▲ Revenue growth
▼ EPS growth

Compare with peers

Behind the score

Revenue and earnings-per-share growth over one year, and revenue growth over three years.

Earnings per share growthUnavailable

The loss per share widened33% base weight · Z-score -1.20Sector median: 0.0976 · MAD: 0.2991

3-year revenue growthUnavailable

Missing · left out of the score · no sector data, so not countedNot counted · remaining weights rescaledSector median: 0.0584 · MAD: 0.0840

Revenue growth25.2%

Yahoo Finance fallback · SEC figure unavailable or out of date · fiscal year to Dec 2025Reported value33% base weight · Z-score 1.96Sector median: 0.0609 · MAD: 0.0974

Profitability

Does it earn well?

6/100

Weak

2/3 inputs reported · Partial data

Since last quarter: No major change

Why

Weaker than most peers on:

▼ ROA
▼ Operating margin

Compare with peers

Behind the score

Return on invested capital, operating margin, and return on assets.

Operating margin-411.9%

SEC filings · 12 months to Jun 2026Reported value33% base weight · Z-score -34.42Sector median: 0.0706 · MAD: 0.1217

Return on assets-50.5%

SEC filings · 12 months to Jun 2026Reported value33% base weight · Z-score -9.72Sector median: 0.0166 · MAD: 0.0537

Return on invested capitalUnavailable

Missing · left out of the score · no sector data, so not countedNot counted · remaining weights rescaledSector median: 0.0471 · MAD: 0.1004

Other data (not scored)

Gross margin-236.7%

Yahoo Finance fallback · SEC figure unavailable or out of date · trailing 12 monthsOutlier capped at sector 5th/95th percentileInformational · 0% composite weightSector median: 0.4697 · MAD: 0.2310

Return on equity-612.8%

SEC filings · 12 months to Jun 2026Outlier capped at sector 5th/95th percentileInformational · 0% composite weightSector median: 0.0330 · MAD: 0.1225

Risk

Debt, liquidity, price swings

Lower

Lower relative risk

3/3 inputs reported · High confidence

Since last quarter: No major change

Why

Stronger than most peers on:

▲ Current ratio
▲ Beta

Compare with peers

Behind the score

Relative to sector peers: 0 = lower relative risk · 1 = moderate · 2 = higher. Based on leverage, beta and liquidity.

Beta0.43

Yahoo Finance · 5-year monthly beta vs the marketReported value33% base weight · Z-score 0.57Sector median: 0.6250 · MAD: 0.3380

Current ratio4.73×

SEC filings · latest balance sheetReported value33% base weight · Z-score 1.55Sector median: 2.5860 · MAD: 1.3850

Debt / equity0.20×

SEC filings · latest balance sheetReported value33% base weight · Z-score 0.10Sector median: 0.2215 · MAD: 0.2039

Valuation, growth and profitability scores: higher is better. Risk: 0 is lower, 2 is higher. Risk is a relative proxy, not a bankruptcy probability. Scores depend on available sector peers.

Questions investors ask about Kura Oncology

Is Kura Oncology getting weaker?: Its latest SEC filing (Aug 12, 2026) showed no major changes. Its overall score is unchanged at 36/100 since Oct 28, 2026.
How is Kura Oncology valued vs its peers?: Priced higher than most peers relative to what it earns. Valuation scores 8/100 against 1,393 healthcare peers. Earnings yield -33.8% vs a peer median of 1.5% (weaker than 100% of peers).Earnings yield -33.8% vs peers 1.5% (weaker than 100% of peers).
Is Kura Oncology growing?: At about the same pace as its peers. Growth scores 56/100 against 1,393 healthcare peers. Revenue growth 25.2% vs a peer median of 6.1% (stronger than 83% of peers).Revenue growth 25.2% vs peers 6.1% (stronger than 83% of peers).
How profitable is Kura Oncology?: Less profitable than most of its peers. Profitability scores 6/100 against 1,393 healthcare peers. Return on assets -50.5% vs a peer median of 1.7% (weaker than 93% of peers).Return on assets -50.5% vs peers 1.7% (weaker than 93% of peers).
How risky is Kura Oncology?: Lower risk relative to 1,393 healthcare peers, judged on debt, liquidity and share-price swings. Current ratio 4.73× vs a peer median of 2.59× (stronger than 72% of peers).Current ratio 4.73× vs peers 2.59× (stronger than 72% of peers). A relative measure, not a bankruptcy probability.

Latest filing: what changed

Quarter ended Jun 30, 2026 · filed Aug 12, 2026 · compared with the quarter ended Mar 31, 2026

No major changes

Worth watching: Kura Oncology is in the bottom fifth of its sector on profitability. From 2021 to 2025, 63% of companies in that position posted a loss over the following year, against 4% for the top fifth.

	Previous quarter	Latest quarter	Change
Revenue (12 months)	71.6M USD	77.2M USD	+7.8%
Net income (12 months)	−294.6M USD	−296.8M USD	+0.7%
Operating margin	-443.5%	-411.9%	+31.6 pts
Free cash flow (12 months)	−84.5M USD	−117.4M USD	+39.0%
Debt	9.7M USD	9.8M USD	+0.4%
Cash	39.1M USD	70.2M USD	+79.7%
Shares outstanding	88.8M	89.0M	+0.2%

From the company’s own SEC filings, as filed. Twelve-month figures roll forward one quarter at a time.

Industry valuation context

Industry: Biotechnology · 132 companies

Valuations in Biotechnology are within their usual range since 2016.

48% of months since 2016 were valued lower than now.
22% of companies are in the most expensive fifth of their own price-to-sales history.
Median price-to-sales is +530% vs the whole market, against a usual +637%.

2016Shaded: most expensive fifth of its range2026

Earnings-based measures are left out for now because many companies in Biotechnology are losing money.

Financials

Fiscal years from SEC annual filings · change vs the prior year

Key ratios	FY 2021	FY 2022	FY 2023	FY 2024	FY 2025	Change
Operating margin	—	—	—	-358.5%	-449.9%	▼ 91 pts
Net margin	—	—	—	-322.9%	-412.9%	▼ 90 pts
Return on assets (ROA)	-24.4%	-29.8%	-34.0%	-22.9%	-37.7%	▼ 15 pts
Return on equity (ROE)	-25.8%	-32.3%	-38.4%	-42.1%	-160.0%	▼ 118 pts
Free cash flow margin	—	—	—	248.4%	-104.8%	▼ 353 pts
Current ratio	23.26×	18.56×	12.26×	9.46×	6.06×	▼ 36%
Quick ratio	—	—	—	9.46×	6.05×	▼ 36%
Debt to equity	—	0.02×	0.02×	0.02×	0.06×	▲ 142%
Interest coverage	—	-610.76×	-107.04×	-119.33×	-200.81×	▼ 68%

KURA price history

Price history is added with the daily price update and will appear after the next one.

Similar companies

Sector leaderboards

BB Biotech AGBBZA.DE100/ 100

Arbutus Biopharma CorporationABUS97/ 100

Q32 Bio Inc.QTTB97/ 100

Bringing the fundamentals into focus…

Overall health

Strength: lower risk than most peers: more short-term liquiditylower risk: more liquidity

Drawback: less profitable than most peersless profitable than peers

Drawback: its shares are priced higher than most peers relative to what it earnspriced higher than peers for its earnings

About average: growth

Ranks #889 of 1,157 healthcare companies (bottom 24%)

See how it ranks against its peers

Worth knowing

Shareholders being diluted. Shares outstanding up 30% from December 2022 to August 2026.

Kura Oncology had 30% more shares at August 2026 than at December 2022, mostly from issuing stock (for pay, acquisitions or fundraising). Each existing share now owns a smaller slice of the business.Kura Oncology had 30% more shares at August 2026 than at December 2022, mostly from issuing stock. Each existing share now owns a smaller slice of the business.

Stock-based pay is a large cost. Stock pay was 55% of revenue in 2025.

Kura Oncology paid employees $37M in stock in 2025, 55% of its $67M revenue. It doesn't use cash, so it flatters cash flow, but it is a real cost to shareholders through dilution.

Valuation signals disagree. Cheaper than 50% of peers on free cash flow, but only 0% on earnings.

Relative to its free cash flow, Kura Oncology looks cheaper than 50% of peers; relative to its earnings, cheaper than only 0%. The valuation score blends the two, so look at which measure fits this business best.

Growing fast, still losing money. Revenue grew faster than 83% of peers, at an operating loss.

Revenue grew faster than 83% of peers, but the business runs at an operating loss (margin -412%).

Questions investors ask about Kura Oncology

Is Kura Oncology getting weaker?

Its latest SEC filing (Aug 12, 2026) showed no major changes. Its overall score is unchanged at 36/100 since Oct 28, 2026.

How is Kura Oncology valued vs its peers?

Priced higher than most peers relative to what it earns. Valuation scores 8/100 against 1,393 healthcare peers. Earnings yield -33.8% vs a peer median of 1.5% (weaker than 100% of peers).Earnings yield -33.8% vs peers 1.5% (weaker than 100% of peers).

Is Kura Oncology growing?

At about the same pace as its peers. Growth scores 56/100 against 1,393 healthcare peers. Revenue growth 25.2% vs a peer median of 6.1% (stronger than 83% of peers).Revenue growth 25.2% vs peers 6.1% (stronger than 83% of peers).

How profitable is Kura Oncology?

Less profitable than most of its peers. Profitability scores 6/100 against 1,393 healthcare peers. Return on assets -50.5% vs a peer median of 1.7% (weaker than 93% of peers).Return on assets -50.5% vs peers 1.7% (weaker than 93% of peers).

How risky is Kura Oncology?

Lower risk relative to 1,393 healthcare peers, judged on debt, liquidity and share-price swings. Current ratio 4.73× vs a peer median of 2.59× (stronger than 72% of peers).Current ratio 4.73× vs peers 2.59× (stronger than 72% of peers). A relative measure, not a bankruptcy probability.

Previous quarter

Latest quarter

Change

Revenue (12 months)

71.6M USD

77.2M USD

+7.8%

Net income (12 months)

−294.6M USD

−296.8M USD

+0.7%

Operating margin

-443.5%

-411.9%

+31.6 pts

Free cash flow (12 months)

−84.5M USD

−117.4M USD

+39.0%

Debt

9.7M USD

9.8M USD

+0.4%

Cash

39.1M USD

70.2M USD

+79.7%

Shares outstanding

88.8M

89.0M

+0.2%

Key ratios

FY 2021

FY 2022

FY 2023

FY 2024

FY 2025

Change

Operating margin

—

-358.5%

-449.9%

▼ 91 pts

Net margin

—

-322.9%

-412.9%

▼ 90 pts

Return on assets (ROA)

-24.4%

-29.8%

-34.0%

-22.9%

-37.7%

▼ 15 pts

Return on equity (ROE)

-25.8%

-32.3%

-38.4%

-42.1%

-160.0%

▼ 118 pts

Free cash flow margin

—

248.4%

-104.8%

▼ 353 pts

Current ratio

23.26×

18.56×

12.26×

9.46×

6.06×

▼ 36%

Quick ratio

—

9.46×

6.05×

▼ 36%

Debt to equity

—

0.02×

0.06×

▲ 142%

Interest coverage

—

-610.76×

-107.04×

-119.33×

-200.81×

▼ 68%